Skip to content

This website is a third-party information service. It does not provide medical care or operate a treatment facility.

CNS Medication Trials

Boston, Massachusetts

CNS medication trials in Boston, MA

58 CNS medication studies are recruiting participants at sites in Boston as of November 17, 2026, according to ClinicalTrials.gov. CNS Medication Trials can help you understand your options and connect with a study team.

Call (888) 927-5768
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

Boston at a glance

  • 58 studies are recruiting at a site in Boston.
  • By phase: Early Phase 1 (1), Phase 1 (4), Phase 1/2 (3), Phase 2 (12), Phase 2/3 (1), Phase 3 (26), Phase 4 (11).
  • By sponsor: industry (37), university, hospital or other (19), government (2).
  • By research area: Depression (20), Multiple Sclerosis (11), Parkinson's Disease (10), Schizophrenia (8), ADHD (5), Epilepsy (2), Migraine (2).
  • Most recent update to one of these records: November 17, 2026.

Depression studies recruiting in Boston

Basic details from each study's public record (the 30 most recently updated of 58). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder

    • Phase 3
    • Ages 18 to 85
    • All sexes
    Sponsor
    Cybin IRL Limited
    Study site
    Adams Clinical Boston
    Registry record
    NCT06793397 · updated
  2. Long-Term Maintenance With Ketamine and Esketamine for Reduction of Suicide in High-Risk Patients With Depression

    • Phase 4
    • Ages 18 to 70
    • All sexes
    Sponsor
    Massachusetts General Hospital
    Study site
    Massachusetts General Hospital
    Registry record
    NCT05450432 · updated
  3. RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses

    • Phase 2
    • Ages 18 to 80
    • All sexes
    Sponsor
    Reunion Neuroscience Inc
    Study site
    Dana Farber Cancer Institute
    Registry record
    NCT07002034 · updated
  4. A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study)

    • Phase 2
    • Ages 18 to 65
    • All sexes
    Sponsor
    Seaport Therapeutics
    Study site
    Seaport Investigator Site
    Registry record
    NCT07065240 · updated
  5. A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)

    • Phase 3
    • Ages 18 to 74
    • All sexes
    Sponsor
    Definium Therapeutics US, Inc.
    Study site
    Adams Clinical Watertown
    Registry record
    NCT07592689 · updated
  6. A Study of Brenipatide in Adult Participants With Major Depressive Disorder

    • Phase 3
    • Ages 18 to 75
    • All sexes
    Sponsor
    Eli Lilly and Company
    Study site
    Adams Clinical Boston
    Registry record
    NCT07412756 · updated
  7. A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder

    • Phase 3
    • Ages 12 to 17
    • All sexes
    Sponsor
    Janssen Research & Development, LLC
    Study site
    Boston Childrens Hospital
    Registry record
    NCT07227454 · updated
  8. A Study of Seltorexant as Monotherapy in Adults and Elderly Participants With Major Depressive Disorder

    • Phase 3
    • Ages 18 to 74
    • All sexes
    Sponsor
    Janssen Research & Development, LLC
    Study site
    Adams Clinical Boston
    Registry record
    NCT07573176 · updated
  9. A Study of Brenipatide (LY3537031) in Adult Participants With Major Depressive Disorder

    • Phase 3
    • Ages 18 to 75
    • All sexes
    Sponsor
    Eli Lilly and Company
    Study site
    Adams Clinical Boston
    Registry record
    NCT07775300 · updated
  10. Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Neurocrine Biosciences
    Study site
    Neurocrine Clinical Site
    Registry record
    NCT06966401 · updated
  11. Cognitive Dysfunction and Inflammation in Depression: Experimental Inhibition Via Infliximab

    • Phase 2
    • Ages 25 to 50
    • All sexes
    Sponsor
    Massachusetts General Hospital
    Study site
    Massachusetts General Hospital
    Registry record
    NCT06136546 · updated
  12. Effects of Intranasal Oxytocin in Patients With Arginine-vasopressin Deficiency

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Elizabeth Austen Lawson
    Study site
    Massachusetts General Hospital, Neuroendocrine Unit
    Registry record
    NCT04789148 · updated

Source: ClinicalTrials.gov. Data processed . See every depression study recruiting in Boston, MA on ClinicalTrials.gov.

Schizophrenia studies recruiting in Boston

  1. A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (EMERGENT TEEN)

    • Phase 3
    • Ages 13 to 17
    • All sexes
    Sponsor
    Bristol-Myers Squibb
    Study site
    Boston Children's Hospital
    Registry record
    NCT07288567 · updated
  2. A Study to Evaluate the Long-term Safety and Tolerability of Xanomeline and Trospium Chloride for the Treatment of Psychiatric Disorders in Children and Adolescents

    • Phase 3
    • Ages 5 to 17
    • All sexes
    Sponsor
    Karuna Therapeutics, Inc., a Bristol Myers Squibb company
    Study site
    Boston Children's Hospital
    Registry record
    NCT07424404 · updated
  3. A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)

    • Phase 3
    • Ages 55 to 90
    • All sexes
    Sponsor
    Karuna Therapeutics, Inc., a Bristol Myers Squibb company
    Study site
    Tufts Medical Center - 800 Washington St - PPDS
    Registry record
    NCT06585787 · updated

Source: ClinicalTrials.gov. Data processed . See every schizophrenia study recruiting in Boston, MA on ClinicalTrials.gov.

ADHD studies recruiting in Boston

  1. A Study to Test the Effects of Centanafadine in Adults With Attention-deficit/Hyperactivity Disorder and Emotional Dysregulation

    • Phase 3
    • Ages 18 to 65
    • All sexes
    Sponsor
    Otsuka Pharmaceutical Development & Commercialization, Inc.
    Study site
    Boston Clinical Trials
    Registry record
    NCT07759154 · updated

Source: ClinicalTrials.gov. Data processed . See every ADHD study recruiting in Boston, MA on ClinicalTrials.gov.

Parkinson's disease studies recruiting in Boston

  1. A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study sites
    Dana Farber Cancer Hospital ( Site 0155) · Massachusetts General Hospital ( Site 0136)
    Registry record
    NCT06623422 · updated
  2. A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)

    • Phase 3
    • Ages 18 and older
    • Female participants
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    Tufts Medical Center ( Site 6052)
    Registry record
    NCT06952504 · updated
  3. A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study sites
    Dana Farber Cancer Institute ( Site 0090) · Massachusetts General Hospital Cancer Center ( Site 0091)
    Registry record
    NCT06966700 · updated
  4. DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer

    • Phase 3
    • Ages 18 and older
    • Female participants
    Sponsor
    AstraZeneca
    Registry record
    NCT06989112 · updated
  5. An Exploratory Study of the Potential for Rational Immune System Manipulation to Prevent Emergence of Synucleinopathy Manifestations in Persons With REM Sleep Behavior Disorder (RBD)

    • Phase 2
    • Ages 50 to 80
    • All sexes
    Sponsor
    Yale University
    Study site
    Massachusetts General Hospital
    Registry record
    NCT06996652 · updated
  6. A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease

    • Phase 3
    • Ages 50 to 85
    • All sexes
    Sponsor
    Hoffmann-La Roche
    Study site
    Massachusetts General Hospital
    Registry record
    NCT07174310 · updated
  7. A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease

    • Phase 2
    • Ages 40 to 80
    • All sexes
    Sponsor
    Neuron23 Inc.
    Study site
    Beth Israel Deaconess Medical Center
    Registry record
    NCT06680830 · updated
  8. A Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (PD) Participants With Motor Fluctuations

    • Phase 2
    • Ages 30 to 80
    • All sexes
    Sponsor
    Appello Pharmaceuticals, Inc.
    Study site
    Beth Israel Deaconess Medical Center (Site #211)
    Registry record
    NCT07432958 · updated

Source: ClinicalTrials.gov. Data processed . See every Parkinson's disease study recruiting in Boston, MA on ClinicalTrials.gov.

Multiple sclerosis (MS) studies recruiting in Boston

  1. Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Dana-Farber Cancer Institute · Massachusetts General Hospital Cancer Center
    Registry record
    NCT03816345 · updated
  2. Dalfampridine Combined With Physical Therapy for Mobility Impairment in Multiple Sclerosis

    • Phase 3
    • Ages 25 to 75
    • All sexes
    Sponsor
    MGH Institute of Health Professions
    Study site
    MGH Institute of Health Professions
    Registry record
    NCT06136728 · updated
  3. Efgartigimod for the Treatment of Acute Optic Neuritis

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Anastasia Vishnevetsky, MD, MPH
    Study sites
    Massachusetts Eye and Ear Infirmary · Massachusetts General Hospital
    Registry record
    NCT06453694 · updated

Source: ClinicalTrials.gov. Data processed . See every multiple sclerosis study recruiting in Boston, MA on ClinicalTrials.gov.

Epilepsy studies recruiting in Boston

  1. Methylphenidate for the Treatment of Epilepsy-related Cognitive Deficits

    • Phase 4
    • Ages 18 and older
    • All sexes
    Sponsor
    VA Office of Research and Development
    Study site
    VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA
    Registry record
    NCT04419272 · updated

Source: ClinicalTrials.gov. Data processed . See every epilepsy study recruiting in Boston, MA on ClinicalTrials.gov.

Migraine studies recruiting in Boston

  1. A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine

    • Phase 3
    • Ages 18 to 75
    • All sexes
    Sponsor
    TriGemX Bio, Inc.
    Study site
    Boston Clinical Trials - Alcanza
    Registry record
    NCT07645924 · updated
  2. A Long-Term Safety Study of Elismetrep (K-304) in the Acute Treatment of Migraine

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    TriGemX Bio, Inc.
    Study site
    Boston Clinical Trials - Alcanza
    Registry record
    NCT07674654 · updated

Source: ClinicalTrials.gov. Data processed . See every migraine study recruiting in Boston, MA on ClinicalTrials.gov.

Ask about studies near Boston

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 17, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded. This site lists only studies that test a medication, as each study is coded in the registry.

CNS Medication Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 927-5768

or send a short form

How should we reach you?

Call